PharmaPlanter’s iPSC-Organoid platform provides a physiologically relevant 3D cellular environment designed to surpass the limitations of traditional 2D cultures. By integrating induced pluripotent stem cell (iPSC) technology with advanced organoid engineering, we create high-fidelity disease models that accurately reflect human organ complexity for drug screening and mechanistic studies.

Our platform enables:

• Advanced iPSC Reprogramming & Editing: We utilize non-integrative technologies to reprogram somatic cells into high-quality iPSCs. Combined with CRISPR/Cas9 gene editing, we generate isogenic cell lines and reporter lines to model specific genetic diseases or track cellular differentiation in real-time.

• Precision 3D Organoid Engineering: Our platform features standardized protocols for the induction and maturation of organ-specific models (including brain, liver, and lung organoids). By precisely controlling the microenvironment and morphogen gradients, we ensure the formation of complex, bioactive 3D architectures that mimic native tissue functions.

• High-Throughput Phenotypic Screening: We offer automated imaging and functional analysis for drug efficacy and toxicity testing. Our organoid-based assays provide superior predictive value for human clinical responses compared to conventional cell lines, significantly de-risking early-stage drug development.

• Multi-Omics & Functional Validation: Every organoid model undergoes rigorous characterization, including single-cell RNA sequencing (scRNA-seq), immunofluorescence, and electrophysiological monitoring (for neural models), ensuring the biological relevance and reproducibility of experimental results.

• Translational Disease Modeling: We bridge the gap between target discovery and clinical trials by utilizing patient-derived iPSCs. This allows for "clinical trials in a dish," enabling personalized medicine approaches and the identification of patient-specific drug responses before advancing to in vivo studies.